Inhibrx (Nasdaq:INBX) - Hisse Senedi Fiyatı, Haberler ve Analizler

INBX Stoklara Genel Bakış

A clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. Daha fazla detay

INBX temel anali̇z
Kar Tanesi Skoru
Değerleme	0/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	0/6
Finansal Sağlık	5/6
Temettüler	0/6

Ödüller

Gelirin yılda 59.66% oranında artması öngörülüyor

Risk Analizi

1 yıldan az nakit akışı var

Anlamlı bir geliri yok ( $2M )

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

Hissedarlar geçen yıl sulandırıldı

Inhibrx, Inc. Rakipler

Viridian Therapeutics

NasdaqCM:VRDN

US$1.6b

ARS Pharmaceuticals

NasdaqGM:SPRY

US$1.3b

Vir Biotechnology

NasdaqGS:VIR

US$928.2m

Syndax Pharmaceuticals

NasdaqGS:SNDX

US$1.4b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Inhibrx
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$34.11
52 Haftanın En Yüksek Seviyesi	US$39.79
52 Haftanın En Düşük Seviyesi	US$14.31
Beta	2.88
11 Aylık Değişim	-0.55%
3 Aylık Değişim	-6.42%
1 Yıllık Değişim	38.66%
33 Yıllık Değişim	55.97%
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	65.34%

Son Haberler & Güncellemeler

Inhibrx Biosciences: Reincorporated And Trying To Find A Niche With Unique Platform

Nov 05

Inhibrx: Continued Advancement Even After INBRX-101 Sale To Sanofi

Jun 07

Recent updates

Inhibrx Biosciences: Reincorporated And Trying To Find A Niche With Unique Platform

Nov 05

Inhibrx, Inc. (NASDAQ:INBX) Shares Could Be 38% Below Their Intrinsic Value Estimate

Mar 23

Hissedar Getirileri

	INBX	US Biotechs	US Pazar
7D	-0.09%	-6.5%	-1.0%
1Y	38.7%	14.6%	30.3%

Getiri vs. Endüstri: INBX geçen yıl % 14.6 oranında getiri sağlayan US Biotechs sektörünü aştı.

Getiri vs Piyasa: INBX geçen yıl % 30.3 oranında getiri sağlayan US Piyasasını aştı.

Fiyat Oynaklığı

Is INBX's price volatile compared to industry and market?
INBX volatility
INBX Average Weekly Movement	1.4%
Biotechs Industry Average Movement	9.7%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: INBX son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: INBX 'nin haftalık oynaklığı geçtiğimiz yıl boyunca 8% dan 1% a düştü.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2009	169	Mark Lappe	inhibrx.com

Inhibrx, Inc. Temel Bilgiler Özeti

Inhibrx'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
INBX temel i̇stati̇sti̇kler
Piyasa değeri	US$1.79b
Kazançlar(TTM)	-US$271.15m
Gelir(TTM)	US$1.78m

1,002x

P/S Oranı

-6.6x

F/K Oranı

INBX aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
INBX gelir tablosu (TTM)
Gelir	US$1.78m
Gelir Maliyeti	US$218.11m
Brüt Kâr	-US$216.32m
Diğer Giderler	US$54.83m
Kazançlar	-US$271.15m

Son Raporlanan Kazançlar

Mar 31, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-5.17
Brüt Marj	-12,132.47%
Net Kâr Marjı	-15,207.80%
Borç/Özkaynak Oranı	1,799.9%

INBX uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

INBX Stoklara Genel Bakış

Ödüller

Risk Analizi

Inhibrx, Inc. Rakipler

NasdaqCM:VRDN

US$1.6b

NasdaqGM:SPRY

US$1.3b

NasdaqGS:VIR

US$928.2m

NasdaqGS:SNDX

US$1.4b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Inhibrx Biosciences: Reincorporated And Trying To Find A Niche With Unique Platform

Inhibrx Files Form 15

Inhibrx: Continued Advancement Even After INBRX-101 Sale To Sanofi

Aventis Inc. completed the acquisition of Inhibrx, Inc. (NasdaqGM:INBX) from a group of shareholders.

Inhibrx, Inc.(NasdaqGM:INBX) dropped from NASDAQ Biotechnology Index

Two Separate Complaints with Nearly Identical Claims Filed in Supreme Court of State of New York, County of New York Against Inhibrx, Inc

Recent updates

Inhibrx Biosciences: Reincorporated And Trying To Find A Niche With Unique Platform

Inhibrx Files Form 15

Inhibrx: Continued Advancement Even After INBRX-101 Sale To Sanofi

Aventis Inc. completed the acquisition of Inhibrx, Inc. (NasdaqGM:INBX) from a group of shareholders.

Inhibrx, Inc.(NasdaqGM:INBX) dropped from NASDAQ Biotechnology Index

Two Separate Complaints with Nearly Identical Claims Filed in Supreme Court of State of New York, County of New York Against Inhibrx, Inc

Two Separate Complaints with Nearly Identical Claims Filed in Supreme Court of State of New York, County of New York Against Inhibrx, Inc

Is Inhibrx (NASDAQ:INBX) Using Debt Sensibly?

First quarter 2024 earnings released: US$1.44 loss per share (vs US$1.12 loss in 1Q 2023)

Executive VP & CFO notifies of intention to sell stock

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

Aventis Inc. entered into a definitive agreement to acquire Inhibrx, Inc. (NasdaqGM:INBX) for $1.4 billion.

Price target decreased by 20% to US$35.50

Aventis Inc. entered into a definitive agreement to acquire Inhibrx, Inc. (NasdaqGM:INBX) for $1.4 billion.

Aventis Inc. entered into a definitive agreement to acquire Inhibrx, Inc. (NasdaqGM:INBX) for $1.4 billion.

Consensus revenue estimates decrease by 22%, EPS upgraded

Consensus revenue estimates increase by 308%, EPS downgraded

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: US$1.10 loss per share (vs US$0.90 loss in 3Q 2022)

Inhibrx, Inc. Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma

Inhibrx, Inc. announced that it has received $200.000633 million in funding

Inhibrx, Inc. announced that it expects to receive $199.999961 million in funding

Consensus revenue estimates increase by 26%

New major risk - Negative shareholders equity

Second quarter 2023 earnings released: US$1.08 loss per share (vs US$0.97 loss in 2Q 2022)

Inhibrx, Inc. Grants Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 85%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Founder & Chief Scientific Officer notifies of intention to sell stock

Founder & Chief Scientific Officer notifies of intention to sell stock

Founder & Chief Scientific Officer notifies of intention to sell stock

Founder & Chief Scientific Officer notifies of intention to sell stock

Consensus forecasts updated

Inhibrx, Inc. Updates Efficacy and Safety Data from Ongoing Phase 1 INBRX-109 Expansion Cohorts for the Treatment of Chondrosarcoma

Consensus revenue estimates increase by 42%

High number of new and inexperienced directors

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Founder & Chief Scientific Officer notifies of intention to sell stock

Founder & Chief Scientific Officer notifies of intention to sell stock

Inhibrx Announces Opportunity for Accelerated Approval Pathway on Functional AAT Serum Levels for INBRX-101 in AATD and Announces Bronchoalveolar Lavage Fluid Detection Results from the Phase 1 Study

Inhibrx down 8% after announcing webcast for pathway for rare disease candidate

Founder & Chief Scientific Officer notifies of intention to sell stock

Consensus revenue estimates fall by 22%

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Founder & Chief Scientific Officer notifies of intention to sell stock

Inhibrx, Inc. Announces Completion of Phase 1 Combination Dose Escalation for INBRX-105

Inhibrx: Potential To Move To Registration Study With INBRX-101

High number of new and inexperienced directors

INBRX-101 Shows Favorable Safety Profile in Patients with Alpha-1 Antitrypsin Deficiency and Demonstrates Potential to Achieve Normal Functional Alpha-1 Antitrypsin Levels with Monthly Dosing

Consensus revenue estimates fall by 17%

Inhibrx, Inc. to Host Webcast Presentation of Topline Results from the Phase 1 Trial of INBRX-101, its Optimized Recombinant Human AAT-Fc Protein for the Treatment of Alpha-1 Antitrypsin Deficiency

First quarter 2022 earnings: EPS and revenues miss analyst expectations

High number of new and inexperienced directors

Price target decreased to US$49.67

Inhibrx, Inc. Announces Formation of A Scientific Advisory Board for Its INBRX-101 program

Inhibrx, Inc., Annual General Meeting, May 25, 2022

Inhibrx, Inc. (NASDAQ:INBX) Shares Could Be 38% Below Their Intrinsic Value Estimate